An investment firm based in Austria manages a total of EUR 50 million in capital, and invests in seed and early stage opportunities in Austria. The firm initially invests up to EUR 1 million, with further capital reserved for potential follow-on rounds.
The firm will consider investing in any area of life science technology, including biotech, medical devices, diagnostics, and also agtech and environmental biotech. The firm is open to investing in early-stage companies that have not yet commenced human clinical trials; however, the firm will only invest in companies that have a working prototype or animal data for their product. While the firm will consider any technology or indication area, the firm generally prefers not to invest in health apps, or in fields such as oncology that incur high costs for clinical development.
The firm focuses on investing in their local area close to Vienna. The firm is open to being a lead investor but prefers not to be the sole investor in a round; the firm syndicates with other VCs and other sources of capital.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment